In our analysis, TNBC accounted for 13.1% of breast cancer subtypes in PIK3CA-M patients, which corresponds to the range reported in the literature, estimated at 5%–13.2% [47,48,49]. This evidence concerns the gene PIK3CA and breast carcinoma.